Fairmount Funds Management LLC
Position in DMRA — Damora Therapeutics, Inc.
CIK 1802528
WEST CONSHOHOCKEN, PA
Position in DMRA
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$225,666,700
New position
Shares Held
8,713,000
first reported quarter
Ownership
14.2%
of shares outstanding
% of Portfolio
16.30%
of 13F equity value
Holder Rank
#2
of 65 holders
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Position in Biotechnology
Healthcare · as of Mar 31, 2026Fairmount Funds Management LLC holds $1,384,339,426 across 12 Biotechnology names. DMRA ranks #1 (16.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | DMRA |
Damora Therapeutics, Inc.
This page
|
8,713,000 | $225,666,700 | |
| 2 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
2,537,191 | $212,921,068 | |
| 3 | COGT |
Cogent Biosciences, Inc.
|
5,503,418 | $211,826,558 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
4,018,101 | $202,673,014 | |
| 5 | ORKA |
Oruka Therapeutics, Inc.
|
3,705,262 | $181,743,101 | |
| 6 | VRDN |
Viridian Therapeutics, Inc.\DE
|
3,914,458 | $76,566,798 | |
| 7 | ELVN |
Enliven Therapeutics, Inc.
|
1,855,644 | $72,741,244 | |
| 8 | JBIO |
Jade Biosciences, Inc.
|
4,553,494 | $63,976,590 |
All Filings in DMRA
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $225,666,700 | 8,713,000 | Shares | Sole | 2026-05-15 | |
| 2026-02-09 | $209,112,000 | 8,713,000 | Shares | Sole | 2026-02-11 | |
| 2025-11-10 | $6,848,250 | 397,000 | Shares | Sole | 2025-11-17 | |
| No filing history on record for this holder in this stock. | ||||||